Revenue
2023
2024
2025
SpyGlass Pharma, Inc. (SGP)
Price$28.94Cached quote
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research & development | $29.2M | $20.0M | $10.0M |
| Operating expenses | $41.4M | $27.1M | $14.2M |
| Operating income | −$41.4M | −$27.1M | −$14.2M |
| EBITDA | −$40.8M | −$26.8M | −$14.1M |
| Net income | −$39.9M | −$29.2M | −$13.3M |
| Basic EPSper basic share | -$17.98 | -$16.31 | -$1.17 |
| Diluted EPSper diluted share | -$17.98 | -$16.31 | -$1.17 |
Owners
Reported shareholders
23.98%of listed shares
RA CAPITAL MANAGEMENT, L.P.8.02M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | 23.98%8.02M shares |
SANDELL SCOTT D | ≈22.10%7.39M shares |
BASKETT FOREST | ≈22.10%7.39M shares |
NEA Management Company, LLC | 22.10%7.39M shares |
Walker Paul Edward | ≈22.10%7.39M shares |
Florence Anthony A. Jr. | ≈22.10%7.39M shares |
Behbahani Ali | ≈22.10%7.39M shares |
Makhzoumi Mohamad | ≈22.10%7.39M shares |
Chang Carmen | ≈22.10%7.39M shares |
Mathers Edward T | ≈18.04%6.04M shares |
NEA 17 GP, LLC / New Enterprise Associates 17, L.P. / NEA Partners 17, L.P. | ≈18.04%6.04M shares |
Yang Rick | ≈18.04%6.04M shares |
Nielsen Kirk G. | ≈9.90%3.31M shares |
Sands Capital Alternatives, LLC | 7.47%2.5M shares |
Pardo Geoffrey B | ≈6.54%2.19M shares |
SAMSARA BIOCAPITAL, LLC | 6.31%2.11M shares |
Kahook Malik Y. | ≈2.61%873.98K shares |
BlackRock, Inc. | 2.13%711.71K shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 2.02%674.14K shares |
Vestal Point Capital, LP | 2.00%670K shares |
Percentages use 33.45M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 9, 2026Form 4 | Khan Bilal ArshadDirector | BuyCommon Stock · indirect | 115.0K | $16.00 | $1.84M | 251.4K |
| Feb 9, 2026Form 4 | Khan Bilal ArshadDirector | BuyCommon Stock | 20.0K | $16.00 | $320.0K | 25.4K |
| Feb 9, 2026Form 4 | Pardo Geoffrey BDirector | BuyCommon Stock · indirect | 312.5K | $16.00 | $5.00M | 2.19M |
| Feb 9, 2026Form 4 | RA Capital Healthcare Fund LP +4Director,TenPercentOwner | BuyCommon Stock · indirect | 248.0K | $16.00 | $3.97M | 2.05M |
| Feb 9, 2026Form 4 | RA Capital Healthcare Fund LP +4Director,TenPercentOwner | BuyCommon Stock · indirect | 3.44M | $16.00 | $55.07M | 5.97M |